NASDAQ:EUCR Eucrates Biomedical Acquisition (EUCR) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free EUCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.02▼$10.0450-Day Range$10.04▼$10.2552-Week Range$9.87▼$10.25Volume12,700 shsAverage Volume2,287 shsMarket Capitalization$42.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Eucrates Biomedical Acquisition alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Eucrates Biomedical Acquisition Stock (NASDAQ:EUCR)Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… EUCR Stock News HeadlinesFebruary 1, 2024 | msn.comPsyence Biomedical Finalizes Strategic Merger AgreementNovember 28, 2023 | msn.comWhat's Going On With Emergent Biosolutions Stock?April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.September 15, 2023 | finanznachrichten.deMineralys Therapeutics, Inc.: Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasFebruary 18, 2023 | marketwatch.com8-K: Eucrates Biomedical Acquisition Corp.February 18, 2023 | msn.comOcean Biomedical stock falls 26%, down 60% since SPAC mergerFebruary 16, 2023 | marketwatch.comOcean Biomedical Debuts on Nasdaq, Shares Trading 11% LowerFebruary 8, 2023 | marketwatch.comGlobal Implantable Biomaterial Market Analysis 2023 by Manufacture, Industry Competition Analysis, Revenue and Forecast to 2028April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 6, 2023 | yahoo.comAesther and Ocean Biomedical Announce Shareholder Approval of Business CombinationFebruary 3, 2023 | marketwatch.com2023 Biomedical Materials Market (New) Research Revenue to Drive Integrate and Take Over Strategies to Expand Market Share to 2027January 12, 2023 | finance.yahoo.comTexas Biomed at forefront of Sudan ebolavirus biomedical R&DJuly 12, 2022 | finance.yahoo.comRealSeq Biosciences Selected in Top 14 Life Sciences Companies for the 2022 BioTools Innovator AcceleratorJune 1, 2022 | benzinga.comBened Biomedical Acquires US Distributor Oryx...March 25, 2022 | wsj.comReviva Pharmaceuticals Holdings Inc.November 7, 2021 | nasdaq.comDo Institutions Own Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR) Shares?November 7, 2021 | finance.yahoo.comWhat You Need To Know About Eucrates Biomedical Acquisition Corp.'s (NASDAQ:EUCR) Investor CompositionOctober 25, 2021 | finance.yahoo.comFlare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and TranslationAugust 18, 2021 | barrons.comEucrates Biomedical Acquisition Corp.July 28, 2021 | thestreet.comAdTheorent Going Public with MCAP Acquisition (MACQ)See More Headlines Receive EUCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:EUCR CUSIPN/A CIK1822929 WebN/A Phone212-710-5220FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.82% Return on Assets2.95% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.81 per share Price / Cash Flow12.36 Book Value($1.25) per share Price / Book-8.03Miscellaneous Outstanding Shares4,210,000Free Float3,386,000Market Cap$42.27 million OptionableNot Optionable Beta-0.07 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Parag Phoolchand Saxena MBA (Age 66)MS, CEO & Director Dr. Evangelos Vergetis (Age 41)Pres, COO & Director Mr. Gonzalo Cordova CFA (Age 67)Chief Financial Officer Mr. Shrikant Sathe (Age 66)Sr. VP Key CompetitorsAIB AcquisitionNASDAQ:AIBYotta AcquisitionNASDAQ:YOTADigital Health AcquisitionNASDAQ:DHACKairous AcquisitionNASDAQ:KACLMoringa AcquisitionNASDAQ:MACAView All Competitors This page (NASDAQ:EUCR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eucrates Biomedical Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
